VINDESINE THERAPY IN MELPHALAN-RESISTANT MULTIPLE-MYELOMA

Abstract Vindesine, a new vinca alkaloid, was administered in thirteen patients with advanced multiple myeloma (stages IIIA and IIIB ), resistant to alkylating agents. Eleven patients received two complete courses and could be evaluated. Six patients ( 55% ) showed objective improvement. This was indicated by a decrease of greater than 50% of pretreatment myeloma protein serum levels, normalization of elevated serum calcium levels, and improvement of haemoglobin concentration and renal function. Neutropenia of short duration, mild paraesthesias and alopecia were noted as side effects.